Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Pfizer Inc. PFE

Healthcare  —  Drug Manufacturers General
28.67 0.26 0.92% as of 25 Sep
Market cap
$161.7B
P/E
37.7×
S&P 500 Member Dividend Champion (10y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Pfizer Inc. (PFE) Price to free cash flow

As of 25 September 2026, Pfizer Inc. (PFE) trades at a price to free cash flow of 16.0×. Over the past ten years it has ranged from 8.0× (October 2021) to 44.3× (July 2024); the current reading is higher than 63% of that period. That is below the Drug Manufacturers General industry median of 17.7× and below the Healthcare sector median of 19.5×.

Price to free cash flow, daily

Annual

Period Price to free cash flow Change
FY2025 17.1× 2.82%
FY2024 16.6× (60.41%)
FY2023 42.0× 268.69%
FY2022 11.4× 0.14%
FY2021 11.4× (36.69%)
FY2020 18.0× (12.10%)
FY2019 20.4× 15.12%
FY2018 17.8× 24.82%
FY2017 14.2× 5.54%
FY2016 13.5× (5.99%)

Quarterly

Period Price to free cash flow Change
Jun 2026 13.5× (26.79%)
Mar 2026 18.4× 7.62%
Dec 2025 17.1× 13.05%
Sep 2025 15.1× 27.75%
42 more quarters

Against its own ten years

Low 8.0× High 44.3×
Ten-year median 14.9×
Current reading's percentile 63

Price to free cash flow against peers

Company Price to free cash flow
SNY Sanofi compare 6.8×
BMY Bristol Myers Squibb Company compare 11.2×
GSK GSK PLC Sponsored ADR compare 12.9×
GILD Gilead Sciences, Inc. compare 14.5×
PFE Pfizer Inc. 16.0×
NVS Novartis AG compare 18.3×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 23.0×
AZN AstraZeneca PLC compare 41.2×
Drug Manufacturers General industry median 17.7×
Healthcare sector median 19.5×
Market median 14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on PFE